TPG, Permira lead race for Cloudnine stake at ₹11,000 crore valuation
TPG Capital and Permira are frontrunners to acquire True North’s 25% stake in Cloudnine Hospitals, alongside a proposed 5–10% primary share issue. Binding bids are expected by mid-August.
What happened
Cloudnine Hospitals · TPG Capital and Permira are frontrunners to buy True North’s 25% Cloudnine stake, alongside a 5-10% primary share issue. The deal could
Key facts
- ₹11,000 crore proposed valuation ($1.15 billion)
- 25% True North stake sale
- 5-10% fresh primary shares planned
- ₹400 crore invested by True North in 2015
- 40 centres as of March 2025
- More than 55 centres after Apollo Cradle and Apollo Fertility acquisition
- ₹1,550 crore Apollo Cradle valuation
- 20 Apollo Fertility IVF centres
- ₹2,000 crore FY26 revenue
- ₹300 crore FY26 EBITDA
- ₹30,000 crore India mother-and-childcare market
- 15% expected annual market growth
Why this matters
The transaction could intensify competition for specialty-care assets as strategic and financial buyers pursue integrated maternity and fertility networks.
What to watch
- Binding-bid participation, bid valuation and whether TPG or Permira seeks board rights or a path to majority control.
- Final split between True North's secondary share sale and the 5–10% primary issuance.
- Management commentary on use of proceeds, target city additions, bed/clinic additions and fertility-lab investments.
- Progress and financial performance of Apollo Cradle and Apollo Fertility integration, especially doctor retention and centre-level profitability.
- Comparable transactions, IPO plans or valuation shifts involving Indian hospital chains, fertility networks and specialty-care providers.
- Any increase in health-insurance coverage, corporate fertility benefits or regulatory changes affecting IVF and assisted reproduction services.
- Prioritize expansion in high-income metro catchments and underpenetrated tier-1 corridors where maternity and fertility demand can support premium occupancy and referral networks.
- Use primary capital to integrate Apollo Cradle and Apollo Fertility operations, including physician retention, unified branding, procurement, EMR systems and cross-referral programs.
- Build a fertility-led growth engine through IVF laboratory capacity, genetic testing partnerships, employer benefits programs and outcome-based patient marketing.
- Strengthen unit economics before a future IPO by improving mature-centre EBITDA, reducing ramp-up time at new hospitals and standardizing clinical staffing ratios.
- Prepare for investor governance by formalizing expansion-return thresholds, quality metrics, regulatory compliance and a credible IPO or sponsor-exit timeline.